Skip to main
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 55%
Buy 35%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

DexCom is viewed favorably because its CGM platform is expanding from intensive diabetes care into the large T2NIT and OTC markets, where CONNECT showed a −1.6% A1c reduction vs. −0.7% for control, ~21% time-in-range improvement, and ~97% adherence over 26 weeks. The company’s Stelo/NutriSense experience suggests durable adoption will be driven by software, coaching, meal logging, and personalized insights, creating a differentiated engagement ecosystem that can support retention and utilization beyond sensor hardware alone. That growth story is reinforced by strong execution, with gross margin of 63.5%, adjusted EBITDA margin of 30.6%, cash and marketable securities of $2.42B, and a reiterated 2026 revenue outlook of $5.16B-$5.25B.

Bears say

DexCom is facing a negative fundamental outlook because its CGM experience still shows meaningful product limitations, including underutilized exercise and sleep functionality, weak engagement with Learn content, and compression lows that reduce overnight glucose-analysis reliability. The company also faces sector-level risks that could pressure growth and profitability, including regulatory delays, pricing pressure from payors and CMS, intense competition, and the high investment required to defend its market position. If CGM penetration fails to expand or competing products weaken its moat, the stock’s premium multiple would be harder to justify despite integration efforts with insulin pumps and broader distribution channels.

DexCom (DXCM) has been analyzed by 20 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 35% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 20 analysts, DexCom (DXCM) has a Buy consensus rating as of Oct 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $90.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $90.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.